Literature DB >> 10582523

Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40).

S Nag1, B K Yee, F Tang.   

Abstract

The present study investigated the neurochemical and behavioural sequelae following chronic intracerebroventricular infusion of beta-amyloid (1-40) in rats. beta-amyloid was either infused intermittently via implanted cannulae on the day of operation and subsequently on postsurgical days 4, 7, 10, and 13 (Experiment 1), or continuously using osmotic pumps for 14 days (Experiment 2). The same amount of beta-amyloid was delivered under both infusion regimes. In both experiments, beta-amyloid infusion led to severe deficits in the acquisition of a spatial reference memory task conducted on postoperative days 10 to 14. The animals were sacrificed on the postoperative day 15 for neurochemical analyses. These included radioenzymatic and radioimmunoassays, designed to determine choline acetyltransferase activity and the contents of neuropeptides (somatostatin, substance P, and neuropeptide Y), respectively. Experiment 2 also included solution-hybridisation-RNAase protection assay for preprosomatostatin mRNA quantification. There was a significant reduction in choline acetyltransferase activity and in the levels of substance P as well as somatostatin and preprosomatostatin mRNA in the cortical mantle of beta-amyloid-treated rats, compared to controls in both experiments. Appreciable reductions in choline acetyltransferase activity and somatostatin level were also apparent in the hippocampus. In contrast, beta-amyloid infusion did not significantly affect the brain level of neuropeptide Y. The present study demonstrated that chronic infusion of beta-amyloid can lead to a reduction in the levels of selected neuropeptides resembling the pattern seen in Alzheimer's disease patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582523     DOI: 10.1016/s0361-9230(99)00196-3

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  4 in total

Review 1.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  Toxin-Induced Experimental Models of Learning and Memory Impairment.

Authors:  Sandeep Vasant More; Hemant Kumar; Duk-Yeon Cho; Yo-Sep Yun; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2016-09-01       Impact factor: 5.923

3.  Somatostatin Ameliorates β-Amyloid-Induced Cytotoxicity via the Regulation of CRMP2 Phosphorylation and Calcium Homeostasis in SH-SY5Y Cells.

Authors:  Seungil Paik; Rishi K Somvanshi; Helen A Oliveira; Shenglong Zou; Ujendra Kumar
Journal:  Biomedicines       Date:  2021-01-02

Review 4.  Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease.

Authors:  Xin-Yi Chen; Yi-Feng Du; Lei Chen
Journal:  Front Mol Neurosci       Date:  2019-01-11       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.